Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02181127 · ClinicalTrials.gov registry record · NA
Closed-Loop Glucagon Administration For Hypoglycemia Treatment
A NA study, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- NA
- Development phase
- 31
- Enrollment target
NCT02181127: Completed NA study, sponsored by Massachusetts General Hospital.
NCT02181127 is a NA study that has completed, run by Massachusetts General Hospital. The registered enrollment target is 31 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02181127, a NA study, has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- NA
- Development phase
- 31 participants
- Enrollment target
Study Summary
This study will test the hypothesis that a wearable automated bionic pancreas system that automatically delivers glucagon only can prevent or treat hypoglycemia vs. usual care for people with type 1 diabetes \> 21 years old.
Interventions
- DEVICE Glucagon-only Bionic Pancreas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 31 participants |
| Start Date | 2014-11 |
| Est. Completion | 2017-04 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02181127
The ClinicalTrials.gov registry entry for NCT02181127 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 31 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Glucagon-only Bionic Pancreas is the first listed.
NCT02181127 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02181127 about?
NCT02181127 is a clinical study titled "Closed-Loop Glucagon Administration For Hypoglycemia Treatment". This study will test the hypothesis that a wearable automated bionic pancreas system that automatically delivers glucagon only can prevent or treat hypoglycemia vs. usual care for people with type 1 diabetes \> 21 years old.
What is the current status of trial NCT02181127?
This trial is currently completed. It is a NA study. The enrollment target is 31 participants. The study started on 2014-11. Estimated completion is 2017-04.
What interventions are being tested in trial NCT02181127?
The interventions under investigation include: Glucagon-only Bionic Pancreas (DEVICE).
Who is sponsoring clinical trial NCT02181127?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.